Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
Status In progress
Process STA
Referral date 01 July 2014

Scoped as part of Batch 35.

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Associate Director: Janet Robertson
Communications manager: Alice Law
Project manager:

Bijal Joshi

Technical Advisor: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
July 2014 Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance